Sierra Oncology Statistics Share Statistics Sierra Oncology has 0
shares outstanding. The number of shares has increased by 97.73%
in one year.
Shares Outstanding n/a Shares Change (YoY) 97.73% Shares Change (QoQ) 62.2% Owned by Institutions (%) n/a Shares Floating 20.06M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 863.96K, so 0% of the outstanding
shares have been sold short.
Short Interest 863.96K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.46
Valuation Ratios The PE ratio is -3.04 and the forward
PE ratio is null.
Sierra Oncology's PEG ratio is
0.42.
PE Ratio -3.04 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 3 P/FCF Ratio -3.65 PEG Ratio 0.42
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sierra Oncology.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.34,
with a Debt / Equity ratio of 0.01.
Current Ratio 8.34 Quick Ratio 8.34 Debt / Equity 0.01 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-868.43K Employee Count 109 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -3K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.02, so Sierra Oncology's
price volatility has been higher than the market average.
Beta 0.02 52-Week Price Change n/a 50-Day Moving Average 54.73 200-Day Moving Average n/a Relative Strength Index (RSI) 77.94 Average Volume (20 Days) 651,457
Income Statement
Revenue n/a Gross Profit n/a Operating Income -94.66M Net Income -94.66M EBITDA -94.36M EBIT -94.66M Earnings Per Share (EPS) -7.14
Full Income Statement Balance Sheet The company has 104.75M in cash and 853K in
debt, giving a net cash position of 103.9M.
Cash & Cash Equivalents 104.75M Total Debt 853K Net Cash 103.9M Retained Earnings -941.25M Total Assets n/a Working Capital n/a
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -78.96M
and capital expenditures -72K, giving a free cash flow of -79.04M.
Operating Cash Flow -78.96M Capital Expenditures -72K Free Cash Flow -79.04M FCF Per Share -5.96
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SRRA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for SRRA.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 22, 2020. It was a
backward
split with a ratio of 1:40.
Last Split Date Jan 22, 2020 Split Type backward Split Ratio 1:40
Scores Altman Z-Score n/a Piotroski F-Score n/a
